Toronto - Free Realtime Quote CAD

Fennec Pharmaceuticals Inc. (FRX.TO)

9.04

0.00

(0.00%)

As of May 8 at 12:11:23 PM EDT. Market Open.

Fennec Pharmaceuticals to Report First Quarter 2025 Financial Results on May 13, 2025

RESEARCH TRIANGLE PARK, N.C., May 08, 2025 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ: FENC; TSX: FRX), a commercial stage specialty pharmaceutical company, today announced that the Company will release its first quarter 2025 financial results before the opening of the U.S. financial markets on Tuesday, May 13, 2025. Management will host a conference call and webcast that day to discuss the Company’s financial and business results. Conference Call & Webcast Detail: Date:Tuesday, May

GlobeNewswire 20 hours ago

FENC
Recent uptick might appease Fennec Pharmaceuticals Inc. (NASDAQ:FENC) hedge funds owners after losing 32% over the past year

Key Insights Given the large stake in the stock by institutions, Fennec Pharmaceuticals' stock price might be...

Simply Wall St. 6 days ago

FENC
Breakeven Is Near for Fennec Pharmaceuticals Inc. (NASDAQ:FENC)

We feel now is a pretty good time to analyse Fennec Pharmaceuticals Inc.'s ( NASDAQ:FENC ) business as it appears the...

Simply Wall St. last month

FENC
Fennec Pharmaceuticals Inc (FENC) Q4 2024 Earnings Call Highlights: Strong Revenue Growth and ...

Fennec Pharmaceuticals Inc (FENC) reports a 40% revenue increase and successful PEDMARK launches in Europe, while navigating competitive challenges and operational expenses.

GuruFocus.com last month

FENC
Q4 2024 Fennec Pharmaceuticals Inc Earnings Call

Q4 2024 Fennec Pharmaceuticals Inc Earnings Call

Thomson Reuters StreetEvents last month

FENC
Wedbush Reviews Fennec Pharmaceuticals' Q4

Fennec Pharmaceuticals' fourth-quarter Pedmark revenue of US$7.9 million beat Wedbush's US$7.6 milli

PREMIUM
MT Newswires last month

FENC
Investing in Fennec Pharmaceuticals (NASDAQ:FENC) five years ago would have delivered you a 38% gain

The main point of investing for the long term is to make money. But more than that, you probably want to see it rise...

Simply Wall St. last month

FENC
Fennec Pharmaceuticals Reports Fourth Quarter and Full-Year 2024 Financial Results and Provides Business Update

~ Achieved Full-Year PEDMARK® Net Product Sales of $29.6 Million, Up 40% Year-Over-Year, and Generated PEDMARK® Q4 2024 Net Product Sales of $7.9 Million ~ ~ Delivered Q4 2024 EBITDA Loss of $0.6 Million and Company Has $26.6 Million in Cash, Cash Equivalents and Short-Term Investments ~ ~ Completed Early Repayment of $13 Million of the Company’s Convertible Debt Facility ~ ~ Continued Momentum in the Adolescent and Young Adult (AYA) Segment and Academic Setting Following Strategic Investments t

GlobeNewswire last month

FENC
Fennec Pharmaceuticals to Report Full Year and Fourth Quarter 2024 Financial Results on March 10, 2025

RESEARCH TRIANGLE PARK, N.C., March 06, 2025 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ: FENC; TSX: FRX), a commercial stage specialty pharmaceutical company, today announced that the Company will release its full year and fourth quarter 2024 financial results before the opening of the U.S. financial markets on Monday, March 10, 2025. Management will host a conference call and webcast that day to discuss the Company’s financial and business results. Conference Call & Webcast Detail:

GlobeNewswire 2 months ago

FENC
Fennec Pharmaceuticals Announces Commercial Launch of PEDMARQSI® In Germany

~ PEDMARQSI is the First and Only Approved Therapy in the EU and U.K. for the Prevention of Ototoxicity, or Hearing Loss, Induced by Cisplatin Chemotherapy in Patients 1 month to <18 Years of Age with Localized, Non-Metastatic Solid Tumors ~ ~ Norgine Pharmaceuticals’ Launch of PEDMARQSI in Germany Accelerates Global Commercialization Strategy ~ ~ Milestone Marks an Important Step in Achieving Fennec’s Mission of Expanding Access to PEDMARQSI to Cancer Patients Across the Globe at Risk of Hearin

GlobeNewswire 2 months ago

FENC
Fennec Pharmaceuticals Announces Pedmarqsi® Positive Recommendation by NICE for the Prevention of Cisplatin-Induced Hearing Loss in England and Wales

~ PEDMARQSI® (anhydrous sodium thiosulfate) is the first and only treatment available within NHS England and Wales for the prevention of cisplatin-induced ototoxicity (hearing loss) in children and young people (1 month-17 years of age) ~ ~ Data from two open-label, randomized Phase 3 trials, SIOPEL 6 (pivotal) and the Clinical Oncology Group (COG) Protocol ACCL0431, demonstrated an approximate 50% reduction in the occurrence of cisplatin-induced ototoxicity in patients treated with cisplatin an

GlobeNewswire 4 months ago

FENC
Fennec Pharmaceuticals Announces Early Partial Repayment of Its Outstanding Convertible Debt Facility with Petrichor Healthcare Capital Management

~ $13 Million Convertible Debt Repayment from Available Cash ~ ~ Elimination of Approximately $1.5 Million in Annual Interest Expense and Potential Equity Overhang of Approximately 1.6 Million Shares ~ RESEARCH TRIANGLE PARK, N.C., Dec. 19, 2024 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ:FENC; TSX: FRX), a specialty pharmaceutical company, today announced the early repayment of $13 million of the Company’s approximately $32 million outstanding convertible debt facility with Petricho

GlobeNewswire 4 months ago

FENC
Fennec Pharmaceuticals to Participate in Upcoming Investor Conference

RESEARCH TRIANGLE PARK, N.C., Dec. 12, 2024 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ:FENC; TSX: FRX), a commercial stage specialty pharmaceutical company, today announced that the Company will be participating in the virtual H.C. Wainwright @ Home Fireside Chat Series taking place on Monday, December 16, 2024 at 11:00 a.m. ET. To access the live webcast, please visit: https://investors.fennecpharma.com/events-and-presentations/events. An archived replay of the webcast will be avai

GlobeNewswire 4 months ago

FENC
Fennec Pharmaceuticals Third Quarter 2024 Earnings: Misses Expectations

Fennec Pharmaceuticals ( NASDAQ:FENC ) Third Quarter 2024 Results Key Financial Results Revenue: US$6.97m (up 7.0% from...

Simply Wall St. 5 months ago

FENC
Fennec Pharmaceuticals Inc (FENC) Q3 2024 Earnings Call Highlights: Strong Sales Growth and ...

Fennec Pharmaceuticals Inc (FENC) reports increased sales and strategic initiatives, despite rising expenses and ongoing litigation challenges.

GuruFocus.com 5 months ago

FENC
Fennec Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Business Update

~ Achieved Third Quarter 2024 Net Product Sales of $7.0 Million ~ ~ Increasing Momentum and Successful Reimbursement in the Adolescent and Young Adult (AYA) Segment Following Strategic Investments to Drive Awareness of Ototoxicity & Adoption of PEDMARK ~ ~ Strengthened Executive Leadership Team with Chief Medical Officer, Chief Commercial Officer & Chief Strategy Officer Appointments ~ ~ Company Has Approximately $40 Million in Cash, Cash Equivalents, and Investment Securities Expected to Fund O

GlobeNewswire 5 months ago

FENC
Fennec Pharmaceuticals to Report Third Quarter 2024 Financial Results on November 7, 2024

RESEARCH TRIANGLE PARK, N.C., Oct. 31, 2024 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ: FENC; TSX: FRX), a commercial stage specialty pharmaceutical company, today announced that the Company will release its third quarter 2024 financial results before the opening of the U.S. financial markets on Thursday, November 7, 2024. Management will host a conference call and webcast that day to discuss the Company’s financial and business results. Conference Call & Webcast Detail: Date:Thursd

GlobeNewswire 6 months ago

FENC
Individual investors account for 31% of Fennec Pharmaceuticals Inc.'s (NASDAQ:FENC) ownership, while hedge funds account for 30%

Key Insights The considerable ownership by individual investors in Fennec Pharmaceuticals indicates that they...

Simply Wall St. 6 months ago

FENC
Fennec Pharmaceuticals Strengthens Executive Leadership Team with Three Key Appointments to Accelerate the Company’s Next Stage of Growth

~ Pierre S. Sayad, PhD, M.S., Appointed Chief Medical Officer ~ ~ Terry Evans Appointed Chief Commercial Officer ~ ~ Christiana Cioffi, MBA, Appointed Chief Strategy Officer ~ RESEARCH TRIANGLE PARK, N.C., Oct. 28, 2024 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ: FENC; TSX: FRX), a commercial stage specialty pharmaceutical company, today announced that it has strengthened its executive leadership team with the appointments of Pierre S. Sayad, PhD, M.S., as chief medical officer, Ter

GlobeNewswire 6 months ago

FENC
The past three years for Fennec Pharmaceuticals (NASDAQ:FENC) investors has not been profitable

In order to justify the effort of selecting individual stocks, it's worth striving to beat the returns from a market...

Simply Wall St. 7 months ago

FENC

Performance Overview

Return	FRX.TO	S&P/TSX Composite index (^GSPTSE)
YTD	+1.92%	+2.61%
1-Year	-28.54%	+12.91%
3-Year	+20.53%	+26.32%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Fennec Pharmaceuticals Inc. (FRX.TO)

Fennec Pharmaceuticals to Report First Quarter 2025 Financial Results on May 13, 2025

Recent uptick might appease Fennec Pharmaceuticals Inc. (NASDAQ:FENC) hedge funds owners after losing 32% over the past year

Breakeven Is Near for Fennec Pharmaceuticals Inc. (NASDAQ:FENC)

Fennec Pharmaceuticals Inc (FENC) Q4 2024 Earnings Call Highlights: Strong Revenue Growth and ...

Q4 2024 Fennec Pharmaceuticals Inc Earnings Call

Wedbush Reviews Fennec Pharmaceuticals' Q4

Investing in Fennec Pharmaceuticals (NASDAQ:FENC) five years ago would have delivered you a 38% gain

Fennec Pharmaceuticals Reports Fourth Quarter and Full-Year 2024 Financial Results and Provides Business Update

Fennec Pharmaceuticals to Report Full Year and Fourth Quarter 2024 Financial Results on March 10, 2025

Fennec Pharmaceuticals Announces Commercial Launch of PEDMARQSI® In Germany

Fennec Pharmaceuticals Announces Pedmarqsi® Positive Recommendation by NICE for the Prevention of Cisplatin-Induced Hearing Loss in England and Wales

Fennec Pharmaceuticals Announces Early Partial Repayment of Its Outstanding Convertible Debt Facility with Petrichor Healthcare Capital Management

Fennec Pharmaceuticals to Participate in Upcoming Investor Conference

Fennec Pharmaceuticals Third Quarter 2024 Earnings: Misses Expectations

Fennec Pharmaceuticals Inc (FENC) Q3 2024 Earnings Call Highlights: Strong Sales Growth and ...

Fennec Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Business Update

Fennec Pharmaceuticals to Report Third Quarter 2024 Financial Results on November 7, 2024

Individual investors account for 31% of Fennec Pharmaceuticals Inc.'s (NASDAQ:FENC) ownership, while hedge funds account for 30%

Fennec Pharmaceuticals Strengthens Executive Leadership Team with Three Key Appointments to Accelerate the Company’s Next Stage of Growth

The past three years for Fennec Pharmaceuticals (NASDAQ:FENC) investors has not been profitable

Performance Overview